LICENSING AGREEMENTS (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Dec. 28, 2020	May 17, 2017	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Jan. 31, 2021	Jan. 08, 2021	Sep. 30, 2020	Dec. 12, 2019	Feb. 02, 2016
Company Paid Cmh								$ 50,000	$ 50,000	$ 40,000
Common Stock Issue								89,286	133	84,656	6,667
Common stock value			$ 14,077		$ 14,077		$ 6,339					$ 100,000
Obligation Of The Initial Payment								$ 300,000	$ 300,000	$ 300,000
License Fees	$ 250,000
Cash Payment In Intial Payment											$ 50,000
License Agreement Description	the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement
License Agreement Description final	Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelz™. during such calendar quarter (the “Continuing Royalty
Restricted Common Stock												$ 431,111
Amortization Expenses					7,479
Carrying Value Of Patent			33,507		$ 33,507
Expiration Period Of Finite-lived Intangible Assets					2025
Expected Amount Of Amortization					$ 9,972
Amortization Expenses			23,021	$ 23,021	69,063	$ 69,063
Option [Member]
Initial Payment											$ 100,000
Creative Medical Health Inc [Member] | Patents [Member]
Amortization Expenses					7,500
Carrying Value Of Patent			47,500		$ 47,500
Expiration Period Of Finite-lived Intangible Assets					May 19, 2027
Expected Amount Of Amortization					$ 10,000
Initial Payment		$ 100,000
Percentage Of Discount On The Basis Of Recent Trading Price		30
Share Price For Two Or More Consecutive Trading Days		0.01
Creative Medical Health Inc [Member] | Patents [Member] | Scenario One [Member]
Payments Upon Signing Agreement With University For The Initiation Of An Irb Clinical Trial		$ 100,000
Payments Upon Completion Of The Irb Clinical Trial		200,000
Payments In The Event Of Commercialization Of Technology		300,000
Creative Medical Health Inc [Member] | Patents [Member] | Scenario Two [Member]
Payments Upon Filing An Ind With The Fda		100,000
Payments Upon Dosing Of The First Patient In A Phase 1-2 Clinical Trial		200,000
Payments Upon Dosing Of The First Patient In Phase 3 Clinical Trial		$ 400,000
Stemspine LLC [Member]
Royalty Payment Percentage		5.00%
Non-royalty Sublease Income Percentage.		50.00%
Stemspine LLC [Member] | Patents [Member]
Amortization Expenses					34,455
Carrying Value Of Patent			167,859		167,859
Expected Amount Of Amortization					46,000
Patent License Agreement [Member]
License Fees					250,000
Amortization Expenses					12,500
Carrying Value Of Patent			212,500		$ 212,500
Expiration Period Of Finite-lived Intangible Assets					2030
Expected Amount Of Amortization					$ 25,000
Multipotent Amniotic Fetal Stem Cells License Agreement [Member] | Patents [Member]
Carrying Value Of Patent			$ 3,498		$ 3,498
Expiration Period Of Finite-lived Intangible Assets					2026
Expected Amount Of Amortization					$ 1,172
Amortization Expenses					879
Number of share issuance cf common stock to jadi cell					$ 180,180